Table 1.

Demographics and clinical characteristics. Continuous characteristics are noted as Mean and associated 95% confidence interval and categorical Characteristics are noted as % (n).

Variable	Overall N=76	Vilazodone N=41	Placebo N=35	P Value
Demographics and Clinical Characteristics
Age	22.2 (21.3–23.1)	22.6 (21.3–23.9)	21.7 (20.4–23.1)	0.228
Male	60 (79.0)	30 (73.2)	30 (85.7)	0.182
Caucasian	40 (54.8)	19 (47.5)	21 (63.6)	0.168
HS Graduate	72 (94.7)	38 (92.7)	34 (97.1)	0.618
HAM-A	2.3 (1.7–2.9)	2.4 (1.6–3.2)	2.2 (1.3–3.1)	0.583
HAM-D	2.3 (1.8–2.8)	2.3 (1.6–3.0)	2.3 (1.5–3.1)	0.954
Cannabis Use Characteristics
Age of Dependence Onset	18.6 (18.1–19.1)	18.4 (17.8–19.0)	18.8 (18.0–19.7)	0.642
Percent of days Using	81.9 (77.3–86.5)	83.3 (77.1–89.4)	80.3 (73.1–87.4)	0.624
Joints/bowls Per Day	3.3 (2.8–3.9)	3.1 (2.6–3.6)	3.7 (2.7–4.7)	0.958
Cannab/Creatinine Ratio	7.1 (4.3–9.8)	4.8 (3.0–6.6)	9.7 (4.1–15.3)	0.183
MCQ Total Score	48.4 (44.8–51.9)	49.9 (45.0–54.9)	46.7 (41.5–51.9)	0.311
MCQ Compulsivity Score	8.3 (7.2–9.5)	8.4 (7.0–9.8)	8.3 (6.5–10.1)	0.497
MCQ Emotionality Score	11.5 (10.3–12.6)	12.1 (10.5–13.8)	10.7 (9.0–12.4)	0.243
MCQ Expectancy Score	13.8 (12.9–14.8)	14.1 (12.7–15.5)	13.5 (12.1–14.9)	0.429
MCQ Purposefulness Score	14.6 (13.6–15.7)	15.0 (13.6–16.4)	14.3 (12.6–15.9)	0.576

^*data available on 74 participants (Placebo n=34 and Vilazodone n=40).